AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who have .
The FDA granted priority review of patritumab deruxtecan for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies.
The US FDA has granted priority review to Daiichi Sankyo and Merck’s BLA for patritumab deruxtecan, to treat non-small cell lung cancer (NSCLC) in adults.